CClinicalTrials.gg
CompletedNCT04819477Updated Mar 18, 2024

Can Austrian Lung Specialists' Assessments of Lung Cancer Screening be Influenced by a Fact Box?"

An interventional study of Fact box and Cates plot in Lung Cancer, sponsored by Karl Landsteiner Institute for Lung Research and Pneumological Oncology. Completed at 1 site in Austria. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-18.

Sponsored by Karl Landsteiner Institute for Lung Research and Pneumological Oncology · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
973
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Study summary

Lung cancer is the most frequently dianosed cancer worldwide. To date, no screening method has been able to establish itself as routinely recommended by the guidelines. In this prospective study with 1:1 randomized questioning using an Internet tool, physicians will be asked in 2 phases (before and after intervention with a fact box) about their assessment of the benefits and risks of lung cancer screening by thoracic computed tomography and about a potential intention to change referral behavior. Randomly assigned, half of the participants will receive the same information in addition to the fact box graphically presented as a Cates plot.

Read the detailed description

The topic of lung cancer screening is highly topical and relevant in that this cancer is the most frequently diagnosed worldwide and has the highest mortality among malignancies. To date, no screening method has been able to establish itself as routinely recommended by the guidelines. In the recently published Dutch-Belgian NELSON study on low dose thoracic CT as a screening method in high-risk patients (smokers and ex-smokers), an - albeit small - reduction in mortality was shown in the screening group vs. the control group).

A prerequisite for a detailed information of the patient about the implementation as well as the advantages and disadvantages of screening is that the physician has risk competence and knows and is able to interpret the screening data. The use of a fact box can be used to improve knowledge of statistical data.

In this prospective study with 1:1 randomized questioning using an Internet tool, physicians will be asked in 2 phases (before and after intervention with a fact box) about their assessment of the benefits and risks of lung cancer screening by thoracic computed tomography and about a potential intention to change referral behavior. Randomly assigned, half of the participants will receive the same information in addition to the fact box graphically presented as a Cates plot.

02

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • Screening
03

In context

Lung Neoplasms

7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.

This study's enrollment of 973 is above the median of 60 across 5,295 interventional studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

Karl Landsteiner Institute for Lung Research and Pneumological Oncology is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Members of the Austrian Society of Pneumology (ÖGP) with a completed pulmonary subject and members of the Austrian Radiological Society (ÖRG), Society for Medical Radiology and Nuclear Medicine with a completed subject.

Exclusion criteria

Exclusion Criteria:

  • Non members of the Austrian Society of Pneumology (ÖGP)
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
973 participants (actual)

Study arms

  • Other
    Cate Plots

    after being asked about current referral practices and assessment of benefits and risks of lung cancer screening, all respondents will receive the Fact box after which they will be randomized into two equal groups. The first group (Arm 1) receives a Cates plot and then another survey about assessment of benefits and risks of lung cancer screening and potential change in referral behavior.

    Behavioral: Fact box · Behavioral: Cates plot

  • Other
    Fact box only

    after being asked about current referral practices and assessment of benefits and risks of lung cancer screening, all respondents will receive the Fact box after which they will be randomized into two equal groups. The second group (Arm 2) receives then a survey about assessment of benefits and risks of lung cancer screening and potential change in referral behavior

    Behavioral: Fact box

Interventions

  • BehavioralFact box

    All physicians surveyed receive a fact box with numerical information on the benefits and harms of chest CT as a screening method. In addition to the fact box, half of the participants will be randomly assigned to receive the same information in the form of a Cates plot.

  • BehavioralCates plot

    In addition to the fact box, half of the participants will be randomly assigned to receive the same information in the form of a Cates plot.

06

What researchers measure

Primary outcomes

  1. CT-Screening

    Proportion of physicians CT-Screening

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
  • Karl Landsteiner Institut für Lungenforschung und Pneumologische Onkologie
    Vienna, 1160, Austria
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04819477
Lead sponsor
Karl Landsteiner Institute for Lung Research and Pneumological Oncology
Responsible party
Sponsor
First posted
Mar 29, 2021
Start date
May 1, 2021
Primary completion
Oct 30, 2021
Completion
Oct 30, 2021
Last update
Mar 18, 2024

Study contacts

Georg-Christian Funk, MD
principal investigator · 2nd Medical Department with Pneumology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion